OASIS DERMATOLOGY GROUP

Ph: (956) 971 - 0404
www.oasisderm.com

Pemphigus

Pemphigus is a rare and potentially life-threatening autoimmune disorder that causes painful, non-healing sores on the skin and mucous membranes. It occurs when the immune system mistakenly produces antibodies that target healthy skin cells, disrupting cell adhesion and leading to blister formation. Pemphigus includes several subtypes, each with unique clinical features and varying responses to treatment. Because of its complexity, pemphigus can be difficult to diagnose and manage. However, advancements in immunosuppressive therapies have greatly improved the prognosis, turning what was once a fatal condition into one that can be managed as a chronic illness.

Etiology and Pathophysiology

Pemphigus is a condition where the body's immune system mistakenly produces antibodies that attack important proteins in the skin, called desmosomal proteins. These proteins, specifically desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3), help hold skin cells together, maintaining the strength and structure of the skin and mucous membranes. When the immune system targets these proteins, it causes the skin cells to separate, leading to the formation of blisters and sores.

There are different types of pemphigus, with pemphigus vulgaris and pemphigus foliaceus being the most common. A rarer and more serious form, called paraneoplastic pemphigus, is linked to certain cancers and tends to be harder to treat.

Types of Pemphigus

- ***Paraneoplastic Pemphigus****:* This is the rarest and most severe form of pemphigus. It is often seen in people with certain types of cancer, such as lymphoma or leukemia. In paraneoplastic pemphigus, painful sores and blisters typically appear in the mouth, lips, and esophagus, along with skin lesions. The disease can be resistant to treatment, and diagnosing it often leads doctors to look for an underlying tumor. In some cases, removing the tumor surgically may help improve the condition. Paraneoplastic pemphigus can also cause serious complications, including respiratory issues and oral problems.
- ***Pemphigus Vulgaris****:* This is the most common form of pemphigus. It begins with painful blisters and sores, often starting in the mouth, then spreading to the skin and mucous membranes, such as the throat and genital areas. In pemphigus vulgaris, the immune system attacks Dsg3, a protein found in the deeper layers of the skin and mucous membranes. The blistering can be very painful and lead to complications like secondary infections and dehydration. Pemphigus vulgaris most commonly affects middle-aged or older adults but can occur at any age.

- ***Pemphigus Foliaceus****:* This form of pemphigus is usually less severe than pemphigus vulgaris and primarily affects the outer layers of the skin. The immune system targets Dsg1, a protein found in the upper layers of the skin. Pemphigus foliaceus typically causes scaly, crusted blisters on the scalp, face, chest, and back, but it rarely affects mucous membranes. Although it is generally less painful than pemphigus vulgaris, it can cause itching and may present cosmetic challenges. Pemphigus foliaceus can affect both adults and children, and it may have a chronic course with relapses.

Clinical Features

- ***Blisters and Erosions****:* : The main feature of pemphigus is the development of soft, flaccid blisters that break open easily, leaving behind painful sores or erosions. These blisters can form on both the skin and mucous membranes.
- ***Oral Lesions****:* In pemphigus vulgaris, painful mouth ulcers are often the first symptom, followed by the formation of blisters and sores on the skin.
- ***Skin Involvement:*** In pemphigus foliaceus, blisters typically begin on the scalp and face and may spread to other areas like the chest and back.
- ***Pain and Itching:*** The blistering and skin erosion in pemphigus can be very painful, particularly on mucosal surfaces. In pemphigus foliaceus, itching may be a more prominent symptom, though pain from the lesions is common in all forms of the disease.

Diagnosis

The diagnosis of pemphigus is confirmed through a combination of clinical evaluation, skin biopsy, and specialized tests. A healthcare provider will assess the patient's symptoms and medical history, looking for characteristic signs such as blisters and erosions on the skin and mucous membranes. A skin biopsy is taken to examine the tissue under a microscope. In pemphigus, the biopsy shows *acantholysis*, which is the separation of skin cells (keratinocytes), a key feature of the disease. A direct immunofluorescence test may be performed to detect IgG antibodies that target desmogleins (the proteins involved in pemphigus), helping to confirm the diagnosis. A blood test may also be performed to identify specific anti-desmoglein antibodies and also help determine which subtype of pemphigus the patient has.

Treatment

While there is no cure for pemphigus, treatment has improved significantly over the years, primarily through the use of immunosuppressive therapies that help manage the condition effectively.

- ***First-line Treatment****:* The mainstay of treatment is systemic corticosteroids, such as prednisone, which work to suppress the overactive immune system. In severe cases, high

doses of corticosteroids may be used initially, followed by a gradual reduction to minimize potential side effects.

- ***Steroid-sparing Agents****:* To limit the long-term side effects of steroids, other medications known as steroid-sparing agents are often added. These include azathioprine, cyclophosphamide, and mycophenolate mofetil. These drugs help to reduce the amount of corticosteroid needed while still controlling the disease.
- ***Biologic Therapies****:* Rituximab is a monoclonal antibody that targets CD20+ B cells, which are involved in the autoimmune process. It is particularly effective in cases that are resistant to or have relapsed after traditional treatments.
- ***Adjunctive Therapies****:*
    - Plasmapheresis or immunoadsorption may be used in severe, life-threatening cases to rapidly remove autoantibodies from the bloodstream, offering quick relief.
    - Topical therapies, including potent corticosteroids or tacrolimus, can help control inflammation and promote healing.
    - Proper care of blisters and open sores is essential to prevent infections, which can worsen the condition.
- ***Supportive Care****:* Patients may require pain management and antibiotics for secondary infections. Good oral hygiene is critical, especially in cases with extensive mucosal involvement. Nutritional support may be necessary for patients with extensive oral lesions, which can impair eating and hydration.

Prognosis

The outlook for pemphigus has greatly improved with the development of modern immunosuppressive therapies. While it remains a chronic condition requiring long-term management, many patients can achieve remission or partial remission with the right treatment. Early diagnosis and prompt initiation of therapy are crucial for a better prognosis.

However, pemphigus can still present significant health risks. Paraneoplastic pemphigus, a rarer and more severe form of the disease often linked to internal cancers, has a poorer prognosis. This form is generally resistant to treatment, which makes managing it more challenging. Despite these challenges, with appropriate care, many patients with pemphigus can lead productive lives.

Conclusion

Pemphigus is a rare but serious autoimmune disorder that causes blisters and erosions on the skin and mucous membranes. With early diagnosis and effective treatment—such as systemic corticosteroids, steroid-sparing agents, and biologic therapies like rituximab—the outlook for individuals with pemphigus has improved significantly. However, because the disease can be complex, especially in its paraneoplastic form, personalized care and ongoing monitoring are essential for achieving the best possible outcomes.

References

- Joly, P., Baricault, S., & Lefebvre, C. (2021). Pemphigus: Diagnosis and treatment. *Autoimmunity Reviews, 20*(8), 102778. https://doi.org/10.1016/j.autrev.2021.102778
- Kampf, C., Moser, C., & Kölblinger, G. (2020). Rituximab in pemphigus: A review of the current treatment paradigm. *Journal of the European Academy of Dermatology and Venereology, 34*(4), 645-654. https://doi.org/10.1111/jdv.16006
- Mehregan, D. R., Jullien, D., & Nguyen, M. (2019). Pemphigus vulgaris: A comprehensive review. *Dermatology Clinics, 37*(2), 173-187. https://doi.org/10.1016/j.det.2018.11.002
- Sasani, M., Khaffaf, K., & Murphy, R. (2018). Pemphigus foliaceus: Diagnosis and management. *Dermatologic Therapy, 31*(3), e12612. https://doi.org/10.1111/dth.12612